Apoptotic Body Surrogates for Antigen-Specific Immune Tolerance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for autoimmune diseases and allergies lack antigen-specific tolerance induction, leading to ineffective treatments with significant side effects and safety concerns, while existing methods for inducing tolerance have shown marginal efficacy and safety issues.
Innovation Solution
The use of apoptotic body surrogates conjugated with immunodominant epitopes to induce antigen-specific tolerance by administering compositions that modulate the immune response, reducing hypersensitivity and transplant rejection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional immunosuppressive therapies are used to treat autoimmune diseases and allergies, then immune response is suppressed, but antigen-specific tolerance is not induced and significant side effects occur
Solution Approach 1:
The invention segments the immune response modulation by using apoptotic body surrogates that specifically target and deliver immunodominant epitopes to antigen-presenting cells, rather than using broad-spectrum immunosuppressants. This segmented approach induces antigen-specific tolerance while sparing other immune functions, thereby reducing side effects.
Solution Approach 2:
The invention introduces apoptotic body surrogates as intermediary carriers that conjugate immunodominant epitopes and deliver them to antigen-presenting cells. These surrogates act as mediators between the epitope and the immune system, enabling specific tolerance induction without the need for direct immunosuppression.
2Reliability
If existing tolerance induction methods are used, then some tolerance effect is achieved, but efficacy is marginal and safety issues persist
Solution Approach 1:
The invention applies local quality by targeting specific immunodominant epitopes rather than using whole antigen preparations. This focused approach concentrates the tolerance-inducing effect on the most immunogenic regions, improving efficacy while simplifying the treatment protocol through epitope-specific conjugation to apoptotic body surrogates.
Solution Approach 2:
The invention changes the physical and chemical parameters of antigen delivery by using apoptotic body surrogates with specific size, surface properties, and conjugation chemistry. These parameter changes enhance uptake by antigen-presenting cells and improve the reliability of tolerance induction compared to conventional methods.
3Object-affected harmful factors
If broad immunosuppression is applied to prevent transplant rejection, then rejection is reduced, but antigen-specific tolerance is not established and long-term safety is compromised
Solution Approach 1:
The invention applies preliminary action by administering apoptotic body surrogates conjugated with donor-specific immunodominant epitopes before or during transplantation. This pre-establishes antigen-specific tolerance to the graft, preventing rejection while avoiding the need for long-term broad immunosuppression, thereby improving long-term safety.
Data Source
AI summary
The present invention provides compositions and methods for inducing antigen-specific tolerance in a subject. In one embodiment, the present invention provides a composition comprising an apoptotic body and an epitope of an antigen. Also provided herein are methods of preparing and administering the composition. The composition and methods provided herein can induce antigen-specific tolerance in a subject.